Bayer's weedkiller cancer legal settlement offers only fleeting relief to shareholders

Bayer still faces about 30,000 unresolved cancer claims that could cost billions, and lawyers vowed to keep pressuring the agriculture-chemicals giant.

German pharmaceutical giant Bayer’s $12.1bn (€10.7bn) settlement to resolve US cancer lawsuits over its flagship weedkiller Roundup and other products offered fleeting relief to investors looking to move on from the legal woes that have hobbled the stock for almost two years.